All
FDA Accepts IND for HT-001 for EGFRi-Associated Rash and Skin Disorders
January 17th 2023Based on the acceptance of its investigational new drug application by the FDA, the safety and tolerability of HT-001 will be evaluated in the phase 2a CLEER of patients with rash and skin disorders associated with EGFR inhibitor therapy.
Perez on Real-World Pola-BR Treatment Outcomes in Patients with R/R LBCL
January 16th 2023In an interview with Targeted Oncology, Ariel Perez, MD, explained the outcomes of patients with R/R large B-cell lymphoma who were treated with Pola-BR in the real-world setting, and the key takeaways from a single-institution study.
ALPINE Trial of Zanubrutinb Improves PFS vs Ibrutinib in CLL and SLL
January 16th 2023In an interview with Targeted Oncology, Jennifer R. Brown, MD, PhD, discussed the findings from the ALPINE study and the effectiveness of zanubrutinib when used for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Preventing and Managing Cytomegalovirus After Hematopoietic Stem Cell Transplant
January 14th 2023In an interview with Targeted Oncology, Guenther Koehne, MD, PhD provided a detailed explanation on the impact of cytomegalovirus reactivation post-transplant, cytomegalovirus reactivation prevention, and refractory cytomegalovirus reactivation.
Opioid Distribution for Terminal Cancer Patients Not Equal for Certain Races and Ethnicities
January 12th 2023Patients with cancer at the end of their life may receive different pain management based on their race/ethnicity. A study has revealed fewer prescriptions and lower doses for 2 racial/ethnic groups.
Zotatifin With Fulvestrant and Abemaciclib Shows Favorable Activity in ER+ Breast Cancer
January 12th 2023In a cohort of 7 patients with ER+ breast cancer, treatment with zotatifin in combination with fulvestrant and abemaciclib led to 2 partial responses and and additional patient with stable disease continuing beyond 24 weeks.